Cystic Fibrosis (CF) is a genetic disorder that affects the respiratory and digestive systems. It is one of the most common life-threatening genetic diseases, primarily affecting individuals of European descent. The prevalence of CF varies among different populations, with an estimated 1 in every 3,500 to 4,000 live births being affected worldwide. However, it is important to note that CF can occur in individuals from any ethnic background. Early diagnosis and advancements in treatment have significantly improved the life expectancy and quality of life for individuals with CF.
Cystic Fibrosis (CF) is a genetic disorder that primarily affects the lungs and digestive system. It is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CF is inherited in an autosomal recessive manner, meaning that both parents must carry a mutated CFTR gene for their child to develop the condition.
The prevalence of CF varies among different populations and ethnic groups. In the United States, approximately 30,000 individuals are living with CF, making it one of the most common genetic disorders. Globally, CF affects around 70,000 people.
The prevalence of CF can also vary geographically. It is more common in populations of European descent, with the highest rates found in individuals of Northern European ancestry. In these populations, the carrier frequency (the proportion of individuals carrying a single CFTR mutation) is estimated to be around 1 in 25 individuals.
Early diagnosis and advancements in treatment have significantly improved the life expectancy and quality of life for individuals with CF. However, it remains a chronic and progressive condition that requires lifelong management and care.